The scientist’s investigation covers issues in Pharmacology, Monoclonal antibody, Drug, Antibody and Biochemistry. His biological study spans a wide range of topics, including Monomethyl auristatin E, Cytotoxic T cell and Potency. His studies in Monomethyl auristatin E integrate themes in fields like Cancer research and Cytotoxicity.
His Monoclonal antibody study incorporates themes from Cancer cell, Molecular biology, Affinity chromatography and In vitro. The Drug study combines topics in areas such as Pharmacokinetics, Drug delivery, Peptide and Monoclonal. His Antibody research includes themes of Gel electrophoresis and Antigen.
His scientific interests lie mostly in Biochemistry, Monoclonal antibody, Antibody, Pharmacology and Prodrug. His research in Monoclonal antibody intersects with topics in Molecular biology and Antigen. Peter D. Senter usually deals with Antibody and limits it to topics linked to Cancer research and Cancer and Cancer cell.
His Pharmacology research integrates issues from Monomethyl auristatin E, Antibody-drug conjugate and Potency. His Prodrug study combines topics from a wide range of disciplines, such as Stereochemistry and Alkaline phosphatase. His Drug research is multidisciplinary, relying on both Brentuximab vedotin and Drug delivery.
His main research concerns Antibody, Biochemistry, Pharmacology, Drug and Cancer research. Monoclonal antibody is the focus of his Antibody research. His Monoclonal antibody study frequently intersects with other fields, such as Antigen.
His Biochemistry course of study focuses on Combinatorial chemistry and Tertiary amine, Amine gas treating and Maleimide. Peter D. Senter has included themes like Brentuximab vedotin, In vitro and Antibody-drug conjugate in his Pharmacology study. His research in Drug tackles topics such as Drug delivery which are related to areas like Stereochemistry.
His primary areas of study are Drug, Biochemistry, Antibody, Drug delivery and Pharmacology. Peter D. Senter has researched Drug in several fields, including Cancer, Pharmacokinetics and Brentuximab vedotin. His work deals with themes such as Monomethyl auristatin E, Anaplastic large-cell lymphoma, Lymphoma and Cancer research, which intersect with Pharmacokinetics.
His Biochemistry study frequently draws connections between related disciplines such as Combinatorial chemistry. Peter D. Senter mostly deals with Monoclonal antibody in his studies of Antibody. His Pharmacology research incorporates elements of Antileukemic agent and Antibody-drug conjugate.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn.
Nature Biotechnology (2003)
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun.
Clinical Cancer Research (2004)
Arming antibodies: prospects and challenges for immunoconjugates
Anna M Wu;Peter D Senter.
Nature Biotechnology (2005)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan.
Monomethylvaline compounds capable of conjugation to ligands
Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis.
Antibody–drug conjugates: targeted drug delivery for cancer
Stephen C Alley;Nicole M Okeley;Peter D Senter.
Current Opinion in Chemical Biology (2010)
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr.
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D Senter;Eric L Sievers.
Nature Biotechnology (2012)
Antibody-Drug Conjugates in Cancer Therapy
Eric L Sievers;Peter D Senter.
Annual Review of Medicine (2013)
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny.
Bioconjugate Chemistry (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: